Front. Endocrinol. Frontiers in Endocrinology Front. Endocrinol. 1664-2392 Frontiers Media S.A. 10.3389/fendo.2020.00507 Endocrinology Correction Corrigendum: Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next? Pinna Graziano * Department of Psychiatry, The Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, United States *Correspondence: Graziano Pinna gpinna@uic.edu; graziano_pinna@yahoo.com

Approved by: Hubert Vaudry, Université de Rouen, France

This article was submitted to Neuroendocrine Science, a section of the journal Frontiers in Endocrinology

 30 07 2020 2020 11 507 11 06 2020 24 06 2020 Copyright © 2020 Pinna. 2020 Pinna

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next? by Pinna, G. (2020). Front. Endocrinol. 11:236. doi: 10.3389/fendo.2020.00236 brexanolone allopregnanolone (3α 5α-THP) postpartum depression fast-acting antidepressant GABAA receptor 5α-reduced steroids 5α-reductase 3α-HSD

In the original article, there was an error. “Allopregnanolone, today best known as brexanolone and marketed as Zulresso™ for the treatment of postpartum depression is part of only two recently Food and Drug Administration (FDA)-approved fast-acting antidepressants, with esketamine nasal spray, an NMDA receptor antagonist used in treatment-resistant depression with suicidality being the other.” However, SPRAVATO® (esketamine) CIII Nasal Spray was approved by the FDA last year to treat treatment-resistant depression in adults when used along with an oral antidepressant, and is not indicated for the treatment of suicidality.

A correction has been made to the Introduction section, First paragraph:

“Allopregnanolone, today best known as brexanolone and marketed as Zulresso™ for the treatment of postpartum depression is part of only two recently Food and Drug Administration (FDA)-approved fast-acting antidepressants, with esketamine nasal spray, an NMDA receptor antagonist used in treatment-resistant depression being the other (1).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.